Clinical Research Directory

Inclusion Criteria: Retrospective pan-cancer cohort: 1. Aged 18 to 80 years; 2. Both genders 3. Clinically and histopathologically confirmed diagnosis of solid malignant tumors, including but not limited to non-small cell lung cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, or breast cancer. 4. Complete clinical data available, including definitive TNM stage and established treatment plan; 5. Archived peripheral blood samples (serum/plasma) collected during routine clinical care. Prospective neoadjuvant chemotherapy (NAC) breast cancer cohort: 1. Female, aged 18 to 80 years (inclusive); 2. Clinically and pathologically confirmed non-metastatic (M0) breast cancer; 3. Planned standard NAC at the study site, with complete pre-treatment ER, PR, and HER2 immunohistochemistry results available; 4. Voluntary participation with signed written informed consent. Prospective metastatic breast cancer cohort: 1. Female, aged 18 to 80 years (inclusive); 2. Clinically and pathologically confirmed metastatic (M1) breast cancer; 3. Planned standard systemic therapy at the study site, with complete ER, PR, and HER2 immunohistochemistry results available; 4. Voluntary participation with signed written informed consent. Benign/Healthy control group: 1. Healthy female volunteers, or female patients with breast fibroadenoma undergoing minimally invasive biopsy during the same period; 2. Voluntary participation with signed written informed consent. Exclusion Criteria: For prospective breast cancer cohorts: 1. History of mastitis, or systemic rheumatic/autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis); 2. Acute or chronic infectious diseases within the past 6 months (e.g., pneumonia, pulmonary tuberculosis, active hepatitis); 3. Long-term use of glucocorticoids, immunosuppressants, biologic agents, or psychotropic medications (short-term or as-needed use excepted); 4. Inability or refusal to provide informed consent.